Loading...
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
Schöffski, P Sufliarsky, J Gelderblom, H Blay, J Strauss, S Stacchiotti, S Rutkowski, P Lindner, L Leahy, Michael G Italiano, A
Schöffski, P
Sufliarsky, J
Gelderblom, H
Blay, J
Strauss, S
Stacchiotti, S
Rutkowski, P
Lindner, L
Leahy, Michael G
Italiano, A
Citations
Altmetric:
Abstract
An inflammatory myofibroblastic tumour (IMFT) is a rare mesenchymal neoplasm characterised by anaplastic lymphoma kinase (ALK) gene rearrangements. We assessed the activity and safety of crizotinib, a tyrosine kinase inhibitor, targeting ALK in patients with advanced IMFT either with or without ALK alterations.
Description
Date
2018-06
Publisher
Collections
Keywords
Type
Article
Citation
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. 2018, 6(6): 431-441 Lancet Respir Med